期刊
SEMINARS IN LIVER DISEASE
卷 34, 期 2, 页码 205-214出版社
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0034-1375960
关键词
drug-induced hepatic steatosis; drug-induced steatohepatitis
资金
- Merck
- Abbvie
- Aegerion
- Salix
- BMS
- Lilly
- Cumberland Pharmaceuticals
- Intercept Pharmaceuticals
- Gilead
- Enterome
- Takeda Pharmaceuticals
Several drugs have been associated with the potential for drug-induced hepatic steatosis (DIHS) and/or phospholipidosis (DIPL), a lysosomal storage disorder. Drug-induced hepatic steatosis is generally a chronic but reversible affliction and may involve drug accumulation in the liver. Fat accumulation may be either macrovesicular or microvesicular in nature. Commonly used medications associated with DINS include amiodarone, valproate, tamoxifen, methotrexate, and some chemotherapeutic and antiretroviral agents. Two recently approved medications for the treatment of hereditary homozygous hypercholesterolemia have also been noted to cause hepatic steatosis. For some compounds such as methotrexate and tamoxifen, the underlying metabolic risk factors such as obesity and metabolic syndrome may exacerbate their potential to cause DIHS and its progression. In this article, the authors discuss the preclinical screening and mechanisms of DINS and DIPL, and review specific examples of drugs commonly used in clinical practice that are known to cause DIHS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据